Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Highlights From Some Recent Articles
Quick take on some upcoming FDA decisions and clinical data
By: Patrick Crutcher
A few comments to highlight some upcoming data or PDUFA events.
Threshold Pharmaceuticals (NASDAQ: THLD) has been quite the stock the past few months after landing a partnership with Merck KGaA and reporting positive top-line PFS data from their Phase 2 study in pancreatic cancer. On Monday, April 2nd @ 10:30AM PST, Threshold will be presenting detailed results from the randomized Phase 2b trial of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Overall survival data will be available in the 2nd-half of 2012.
Top-line data reported in February showed the following:
The median progression-free survival (PFS) was 5.6 months for patients treated with gemcitabine in combination with TH-302 at 240 mg/m2 and 340 mg/m2 compared to 3.6 months for patients…
Publicado en Chimera Research Group.